Advertisement

Index by author

April 01, 2022; Volume 101,Issue 4

  1. Allinne, Jeanne

    1. Multipathway In Vitro Pharmacological Characterization of Specialized Proresolving G Protein-Coupled Receptors
      Jon Merlin, Julia Park, Teresa H. Vandekolk, Stewart A. Fabb, Jeanne Allinne, Roger J. Summers, Christopher J. Langmead and Darren M. Riddy
      Molecular Pharmacology April 2022, 101 (4) 246-256; DOI: https://doi.org/10.1124/molpharm.121.000422

  2. Baffi, Timothy R.

    1. mTOR Regulation of AGC Kinases: New Twist to an Old Tail
      Timothy R. Baffi and Alexandra C. Newton
      Molecular Pharmacology April 2022, 101 (4) 213-218; DOI: https://doi.org/10.1124/molpharm.121.000310

  3. Blackwell, Daniel J.

    1. A High-Throughput Screening Assay to Identify Drugs that Can Treat Long QT Syndrome Caused by Trafficking-Deficient KV11.1 (hERG) Variants
      Christian L. Egly, Daniel J. Blackwell, Jeffrey Schmeckpeper, Brian P. Delisle, C. David Weaver and Björn C. Knollmann
      Molecular Pharmacology April 2022, 101 (4) 236-245; DOI: https://doi.org/10.1124/molpharm.121.000421

  4. Brognard, John

    1. Open Access
      Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer
      Pedro Torres-Ayuso and John Brognard
      Molecular Pharmacology April 2022, 101 (4) 191-200; DOI: https://doi.org/10.1124/molpharm.121.000306

  5. Cobb, Melanie H.

    1. CCT and CCT-Like Modular Protein Interaction Domains in WNK Signaling
      Clinton A. Taylor and Melanie H. Cobb
      Molecular Pharmacology April 2022, 101 (4) 201-212; DOI: https://doi.org/10.1124/molpharm.121.000307

  6. Curukovic, Adna

    1. Open Access
      G-Protein Coupled Receptor Signaling and Mammalian Target of Rapamycin Complex 1 Regulation
      Chase H. Melick, Tshering D. Lama-Sherpa, Adna Curukovic and Jenna L. Jewell
      Molecular Pharmacology April 2022, 101 (4) 181-190; DOI: https://doi.org/10.1124/molpharm.121.000302

  7. Delisle, Brian P.

    1. A High-Throughput Screening Assay to Identify Drugs that Can Treat Long QT Syndrome Caused by Trafficking-Deficient KV11.1 (hERG) Variants
      Christian L. Egly, Daniel J. Blackwell, Jeffrey Schmeckpeper, Brian P. Delisle, C. David Weaver and Björn C. Knollmann
      Molecular Pharmacology April 2022, 101 (4) 236-245; DOI: https://doi.org/10.1124/molpharm.121.000421

  8. Egly, Christian L.

    1. A High-Throughput Screening Assay to Identify Drugs that Can Treat Long QT Syndrome Caused by Trafficking-Deficient KV11.1 (hERG) Variants
      Christian L. Egly, Daniel J. Blackwell, Jeffrey Schmeckpeper, Brian P. Delisle, C. David Weaver and Björn C. Knollmann
      Molecular Pharmacology April 2022, 101 (4) 236-245; DOI: https://doi.org/10.1124/molpharm.121.000421

  9. Ellis, Bradley

    1. A Recombinant Dimethylarginine Dimethylaminohydrolase-1–Based Biotherapeutics to Pharmacologically Lower Asymmetric Dimethyl Arginine, thus Improving Postischemic Cardiac Function and Cardiomyocyte Mitochondrial Activity
      Young Lee, Jaipal Singh, Susan R. Scott, Bradley Ellis, Pinar Zorlutuna and Meijing Wang
      Molecular Pharmacology April 2022, 101 (4) 226-235; DOI: https://doi.org/10.1124/molpharm.121.000394

  10. Fabb, Stewart A.

    1. Multipathway In Vitro Pharmacological Characterization of Specialized Proresolving G Protein-Coupled Receptors
      Jon Merlin, Julia Park, Teresa H. Vandekolk, Stewart A. Fabb, Jeanne Allinne, Roger J. Summers, Christopher J. Langmead and Darren M. Riddy
      Molecular Pharmacology April 2022, 101 (4) 246-256; DOI: https://doi.org/10.1124/molpharm.121.000422
« Previous (Pages : 1 2 3 4 5 ... 5) Next »
Back to top

In this issue

Advertisement